Form 4: Ventyx Biosciences Chief Scientific Officer Sells Shares

Ventyx Biosciences' Chief Scientific Officer, John Nuss, sold 21,119 shares of common stock at an average price of $2.36 per share on December 27, 2024.

Summary

• John Nuss, the Chief Scientific Officer of Ventyx Biosciences, sold 21,119 shares of the company's common stock on December 27, 2024.
• The shares were sold at a weighted average price of $2.36, with individual sales occurring between $2.36 and $2.365 per share.
• Following the transaction, Mr. Nuss directly owns 464,582 shares of Ventyx Biosciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing for an insider stock sale. It doesn't inherently indicate positive or negative sentiment, but the market may interpret it based on the context.

Industry Context

This is a routine SEC Form 4 filing, which is common when company insiders trade shares. It provides transparency into the transactions of company officers.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The sale by the Chief Scientific Officer is not unusual, but the market may react to the sale depending on the size of the transaction and the overall sentiment towards the company.

Stakeholder Impact

• The stock sale by a key officer may be of interest to shareholders, as it could be interpreted as a signal of the officer's confidence in the company's future prospects.

Key Dates

Keywords

Ventyx Biosciences, insider trading, stock sale, John Nuss, Chief Scientific Officer, VTYX